KALVKalVista Pharmaceuticals Inc
KALV
KalVista Pharmaceuticals Inc3,138
Mkt Cap
$993.2MVolume
629,974.0052W High
$21.3152W Low
$9.83PE Ratio
-4.85KALV Fundamentals
Price
$19.39Prev Close
$19.95Open
$19.9250D MA
$16.82Beta
0.85Avg. Volume
1.22MEPS (Annual)
-$3.23P/B
-364.06Rev/Employee
$267,698.18$806.04
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15...
Business Wire·4d ago
Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold
Wall Street Zen lowered KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday...
MarketBeat·7d ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVistas Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each...
Business Wire·10d ago
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High - Should You Buy?
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 52-Week High - Time to Buy...
MarketBeat·10d ago
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. One...
MarketBeat·11d ago
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV
Hennion & Walsh Asset Management Inc. raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 93.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 341,8...
MarketBeat·12d ago
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership...
Business Wire·13d ago
HC Wainwright Has Negative Forecast for KALV FY2028 Earnings
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at HC Wainwright cut their FY2028 earnings estimates for shares of KalVista Pharmaceuticals in a research report...
MarketBeat·13d ago
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells $2,960,232.75 in Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the firm's stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total value of $2,960,232.75. Following the...
MarketBeat·14d ago
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the business's stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $18.28, for a total value of $730,944.08...
MarketBeat·15d ago
<
1
2
...
>